Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 3 , Pages 266-269, July 2010

Escherichia coli resistance to quinolones at a comprehensive cancer center☆

  • Coralia N. Mihu

      Affiliations

    • The UT M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Department of Infectious Diseases, Infection Control and Employee Health, The UT M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Tel.: +1-713-792-2972; fax: +1-713-794-4351.
    • ,
  • Paul R. Rhomberg

      Affiliations

    • Jones Microbiology Institute Laboratories, North Liberty, IA 52317, USA
    • ,
  • Ronald N. Jones

      Affiliations

    • Jones Microbiology Institute Laboratories, North Liberty, IA 52317, USA
    • ,
  • Elizabeth Coyle

      Affiliations

    • University of Houston College of Pharmacy, Houston, TX 77204, USA
    • ,
  • Randall A. Prince

      Affiliations

    • University of Houston College of Pharmacy, Houston, TX 77204, USA
    • ,
  • Kenneth V. Rolston

      Affiliations

    • The UT M.D. Anderson Cancer Center, Houston, TX 77030, USA

Received 6 November 2009; accepted 14 February 2010. published online 17 May 2010.

Abstract 

As part of Meropenem Yearly Susceptibility Test Information Collection/USA Surveillance Programme, we monitored the occurrence of quinolone resistance in Escherichia coli over a 10-year period. A total of 271 E. coli isolates from our institution were tested over a 10-year period. Screening for quinolone resistance (qnr) gene was performed. A decline in susceptibility of E. coli isolates to quinolones and aminoglycosides was noted over the 10-year span (P < 0.0001), which was significantly reduced compared with the average susceptibility of all sites. Introduction of quinolone prophylaxis has led to a significant decline in susceptibility of E. coli to all quinolones. The organisms remain susceptible to carbapenems, cefepime, and piperacillin/tazobactam. Periodic surveillance allows for detection of resistance patterns and adjustment of empiric antibiotic choice in patients at high risk for infection.

Keywords: Escherichia coli, Resistance, Quinolones

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ C.N.M., P.R.R., and K.V.R. have none to declare. E.C has received research funding from Cubist, is a consultant for Astellas and Cubist, and is on the speakers' bureau for Pfizer and Cubist. R.A.P. has received research support from Merck, Astellas, and Enzon. R.N.J. has received research/education grants from AB BIODISK, Abbott, API, Arpida, Astellas, AstraZeneca, Avexa, Bayer, bioMerieux, Cadence, Cempra, Cerexa, Cornerstone, Cubist, Daiichi, Elan, Elanco, Enanta, Forest, GlaxoSmithKline, Johnson & Johnson (Ortho McNeil), Merck, Novartis, Optimer, Ordway, Pacific Beach, Pfizer, Protez, Replidyne, Schering-Plough, Sequoia, Shionogi, Theravance, TREK Diagnostics, ViroPharma, and Wyeth.

PII: S0732-8893(10)00050-7

doi:10.1016/j.diagmicrobio.2010.02.014

Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 3 , Pages 266-269, July 2010

Article Tools

* Image Usage & Resolution